A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells

Despite striking improvements in the diagnosis and care of human cancer, treatment resistance remains to this day an issue in some hard-to-treat cancers. Chondrosarcomas (CSs) constitute the second most common primary bone tumor in adults [1]. Because these cartilaginous tumors exhibit resistance to chemotherapy and conventional radiation therapy, complete surgical resection still remains the primary treatment, with a 10-year survival rate comprised between 30% and 80% depending on the grade. A significant number of patients experience relapse, metastasis or present unresectable disease with poor clinical outcome and high lethality (grade III).

Source: Radiotherapy and Oncology - July 23, 2020 Category: Radiology Authors: Guillaume Vares, Vidhula Ahire, Shigeaki Sunada, Eun Ho Kim, Sei Sai, Fran çois Chevalier, Paul-Henri Romeo, Tadashi Yamamoto, Tetsuo Nakajima, Yannick Saintigny Tags: Original Article Source Type: research